

Stephan Mielke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6379665/publications.pdf>

Version: 2024-02-01

100
papers

8,962
citations

71061

41
h-index

43868

91
g-index

106
all docs

106
docs citations

106
times ranked

9855
citing authors

#	ARTICLE	IF	CITATIONS
1	Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals. <i>Med</i> , 2022, 3, 137-153.e3.	2.2	19
2	NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals. <i>Molecular Medicine</i> , 2022, 28, 20.	1.9	18
3	Lineage-specific early complete donor chimerism and risk of relapse after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 753-759.	1.3	8
4	Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019. <i>British Journal of Haematology</i> , 2022, 197, 82-96.	1.2	9
5	Results of a multicenter phase I/II trial of TCR $\alpha\beta$ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients. <i>Bone Marrow Transplantation</i> , 2022, 57, 423-430.	1.3	27
6	Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. <i>Haematologica</i> , 2021, 106, 363-374.	1.7	26
7	The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study. <i>Bone Marrow Transplantation</i> , 2021, 56, 20-29.	1.3	1
8	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 622-634.	1.3	9
9	Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study. <i>Bone Marrow Transplantation</i> , 2021, 56, 1171-1179.	1.3	30
10	COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. <i>Leukemia</i> , 2021, 35, 2885-2894.	3.3	153
11	Targeting the $\alpha\text{v}\beta\text{3}$ integrin/TGF- β axis improves natural killer cell function against glioblastoma stem cells. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	117
12	Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1403-1415.	5.1	222
13	Abatacept as salvage therapy in chronic graft-versus-host disease—a retrospective analysis. <i>Annals of Hematology</i> , 2021, 100, 779-787.	0.8	10
14	Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. <i>Leukemia</i> , 2021, 35, 3585-3588.	3.3	72
15	Validating a Machine Learning Grading System for Acute Gvhd. a Study on Behalf of the EBMT Transplant Complications Working Party. <i>Blood</i> , 2021, 138, 1809-1809.	0.6	0
16	Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. <i>EBioMedicine</i> , 2021, 74, 103705.	2.7	161
17	Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. <i>Leukemia</i> , 2020, 34, 283-292.	3.3	48
18	Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. <i>Lancet Haematology</i> , the, 2020, 7, e28-e39.	2.2	94

#	ARTICLE	IF	CITATIONS
19	Excretion of <i>Ascaris lumbricoides</i> following reduced-intensity allogeneic hematopoietic stem cell transplantation and consecutive treatment with mebendazole. <i>Transplant Infectious Disease</i> , 2020, 22, e13224.	0.7	3
20	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020, 105, 297-316.	1.7	230
21	Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. <i>Blood Advances</i> , 2020, 4, 3357-3367.	2.5	27
22	Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	23
23	Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. <i>Journal of Hematology and Oncology</i> , 2020, 13, 87.	6.9	44
24	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematology</i> , 2020, 7, e157-e167.	2.2	319
25	Donor-cell leukemia with novel genetic features 2 years after sex-mismatched T cell-depleted haploidentical stem cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 899-901.	0.8	1
26	ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia. <i>Leukemia</i> , 2020, 34, 1907-1923.	3.3	20
27	Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 629-637.	2.5	48
28	Treosulfan conditioning for allogeneic transplantation in multiple myeloma improved overall survival in first line hematopoietic stem cell transplantation a large retrospective study by the Chronic Malignancies Working Party of the EBMT. <i>British Journal of Haematology</i> , 2020, 189, e213-e217.	1.2	10
29	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 47-58.	1.7	51
30	Inflammation-induced tissue damage mimicking GvHD in human skin models as test-platform for immunotherapeutics. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2020, 37, 429-440.	0.9	1
31	Prediction of Relapse after Allogeneic Stem Cell Transplantation Using Individualized Minimal Residual Markers; The Prospective Nordic Study NMDSG14B. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
32	Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. <i>Leukemia</i> , 2019, 33, 2710-2719.	3.3	28
33	Allodepleted T-cell immunotherapy after haploidentical hematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxis. <i>British Journal of Haematology</i> , 2019, 186, 754-766.	1.2	20
34	The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. <i>Blood Advances</i> , 2019, 3, 4034-4042.	2.5	63
35	Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2019, 380, 45-56.	13.9	2,594
36	BEAM Vs Cyclophosphamide-Based Conditioning Regimen in Aggressive Multiple Sclerosis: A Retrospective Analysis of European Blood and Marrow Transplantation Society. <i>Blood</i> , 2019, 134, 3313-3313.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Unique Complications and Limitations of Haploidentical Hematopoietic Cell Transplant. , 2018, , 307-323.		0
38	Photodepletion to Promote Immune Reconstitution Without Graft-Versus-Host Disease After HLA-Haploidentical Transplantation. , 2018, , 81-88.		0
39	Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies. Blood, 2018, 132, 120-120.	0.6	1
40	Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with <i>t(9;22)(q34;q11)</i> -positive acute lymphoblastic leukemia. Haematologica, 2017, 102, e160-e162.	1.7	18
41	Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Annals of Hematology, 2017, 96, 1463-1470.	0.8	48
42	Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. Journal of Hematology and Oncology, 2017, 10, 130.	6.9	38
43	An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight, 2017, 2, e89798.	2.3	166
44	Hydroa Vacciniforme-like Skin Lesions in Epstein-Barr-Virus-associated T-cell Lymphoproliferation with Subsequent Development of Aggressive NK/T-cell Lymphoma. Acta Dermato-Venereologica, 2017, 97, 379-380.	0.6	3
45	New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease. British Journal of Clinical Pharmacology, 2016, 82, 1171-1179.	1.1	28
46	Interactions of donor sources and media influence the histomorphological quality of full-thickness skin models. Biotechnology Journal, 2016, 11, 1352-1361.	1.8	6
47	Adoptive Immunotherapy for Infection Control Using Antigen-Specific Donor-Derived T Cells After Transplantation. , 2016, , 889-908.		0
48	Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features. Biology of Blood and Marrow Transplantation, 2016, 22, 1988-1996.	2.0	40
49	International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biology of Blood and Marrow Transplantation, 2016, 22, 4-10.	2.0	487
50	Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL. Blood, 2016, 128, 1226-1226.	0.6	29
51	Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib. Blood, 2016, 128, 4561-4561.	0.6	10
52	An Early Biomarker Algorithm Predicts Lethal Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation. Blood, 2016, 128, 509-509.	0.6	1
53	A first vascularized skin equivalent for as an alternative to animal experimentation. ALTEX: Alternatives To Animal Experimentation, 2016, 33, 415-422.	0.9	77
54	Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment. Blood, 2016, 128, 510-510.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 3365-3369.	0.6	2
56	Boost and loss of immune responses against tumor-associated antigens in the course of pregnancy as a model for allogeneic immunotherapy. <i>Blood</i> , 2015, 125, 261-272.	0.6	12
57	Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. <i>Haematologica</i> , 2014, 99, 836-847.	1.7	160
58	Diagnosis and treatment of cytomegalovirus 2013. <i>Current Opinion in Hematology</i> , 2014, 21, 470-475.	1.2	14
59	Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus. <i>Clinical Transplantation</i> , 2014, 28, 1410-1415.	0.8	6
60	Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. <i>Blood</i> , 2014, 124, 2034-2045.	0.6	178
61	Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. <i>Blood</i> , 2013, 122, 227-238.	0.6	97
62	Boost and Loss Of Immune Responses Against Tumor-Associated Antigens In The Course Of Pregnancy As a Model For Immunotherapy. <i>Blood</i> , 2013, 122, 4505-4505.	0.6	1
63	Prevention of major infectious complications by pre-emptive enterostomy in patients awaiting allogeneic stem cell transplantation. <i>International Journal of Colorectal Disease</i> , 2012, 27, 1683-1685.	1.0	0
64	Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1125-1136.	2.0	20
65	Immune Responses Against the Tumor-Associated Antigens WT1, MUC-1, PRAME and HER2/Neu in 114 Prospectively Screened Healthy Donors: Effects of Gender and Prior Pregnancy and Implications for Immunotherapy. <i>Blood</i> , 2012, 120, 4115-4115.	0.6	1
66	Selectively T Cell-Depleted Allografts from HLA-Matched Sibling Donors Followed by Low-Dose Posttransplantation Immunosuppression to Improve Transplantation Outcome in Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1855-1861.	2.0	52
67	Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. <i>Haematologica</i> , 2011, 96, 432-440.	1.7	114
68	Reduction in Incidence of Severe Infections by Transplantation of High Doses of Haploidentical T Cells Selectively Depleted of Alloreactive Units. <i>Blood</i> , 2011, 118, 3020-3020.	0.6	5
69	Life-Threatening Infection Caused by Daptomycin-Resistant <i>Corynebacterium jeikeium</i> in a Neutropenic Patient. <i>Journal of Clinical Microbiology</i> , 2009, 47, 2328-2331.	1.8	30
70	Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: results from a case series. <i>Leukemia and Lymphoma</i> , 2009, 50, 2071-2074.	0.6	10
71	Management of relapse and minimal residual disease after stem cell allotransplantation. , 2009, , 409-416.		3
72	Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. <i>Blood</i> , 2009, 113, 2245-2255.	0.6	113

#	ARTICLE	IF	CITATIONS
73	Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease. <i>Blood</i> , 2009, 114, 2829-2836.	0.6	32
74	A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. <i>Blood</i> , 2008, 111, 4392-4402.	0.6	107
75	Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. <i>Blood</i> , 2008, 111, 236-242.	0.6	337
76	Standard Operating Procedures (SOP). , 2008, , 802-822.		0
77	Fatal Leukoencephalopathy after Reduced-Intensity Allogeneic Stem Cell Transplantation. <i>Oncology Research and Treatment</i> , 2007, 30, 49-52.	0.8	1
78	Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. <i>Blood</i> , 2007, 110, 1603-1606.	0.6	189
79	High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. <i>Blood</i> , 2007, 110, 770-775.	0.6	32
80	Graft-versus-leukemia effects associated with detectable Wilms tumor-1-specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. <i>Blood</i> , 2007, 110, 1924-1932.	0.6	158
81	Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. <i>Blood</i> , 2007, 110, 1689-1697.	0.6	69
82	Individualized pharmacotherapy with paclitaxel. <i>Current Opinion in Oncology</i> , 2007, 19, 586-589.	1.1	30
83	Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1216-1223.	2.0	134
84	Leukemia-Associated Antigen Specific T-Cell Responses Following Combined PR1 and WT1 Peptide Vaccination in Patients with Myeloid Malignancies.. <i>Blood</i> , 2007, 110, 287-287.	0.6	2
85	Chronic GVHD and Pretransplantation Abnormalities in Pulmonary Function Are the Main Determinants Predicting Worsening Pulmonary Function in Long-term Survivors after Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1261-1269.	2.0	60
86	T Cell Depleted Peripheral Blood Stem Cell Allotransplantation with T Cell Add Back for Patients with Hematological Malignancies: Effect of Chronic GVHD on Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1318-1325.	2.0	55
87	Peripheral neuropathy: A persisting challenge in paclitaxel-based regimes. <i>European Journal of Cancer</i> , 2006, 42, 24-30.	1.3	170
88	Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. <i>European Journal of Cancer</i> , 2006, 42, 2893-2896.	1.3	150
89	Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. <i>Blood</i> , 2006, 107, 1688-1695.	0.6	90
90	High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. <i>Blood</i> , 2006, 108, 1291-1297.	0.6	333

#	ARTICLE	IF	CITATIONS
91	FOXP3-Positive Regulatory T-Cells in Acquired Aplastic Anemia.. Blood, 2006, 108, 2248-2248.	0.6	6
92	Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood, 2005, 106, 1123-1129.	0.6	139
93	Association of Paclitaxel Pharmacokinetics with the Development of Peripheral Neuropathy in Patients with Advanced Cancer. Clinical Cancer Research, 2005, 11, 4843-4850.	3.2	113
94	Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel. Clinical Cancer Research, 2005, 11, 8097-8104.	3.2	170
95	T-Cell Responses Directed against Multiple HLA-A*0201-Restricted Epitopes Derived from Wilms' Tumor 1 Protein in Patients with Leukemia and Healthy Donors: Identification, Quantification, and Characterization. Clinical Cancer Research, 2005, 11, 8799-8807.	3.2	105
96	Reconstitution of Regulatory T Cells after Selective Depletion of CD25+ Host-Reactive Donor Lymphocytes from Allografts and Association with Acute Graft-Versus-Host-Disease.. Blood, 2005, 106, 595-595.	0.6	1
97	T-Cell Depleted PBSCT Mitigates Acute GVHD, but Preserves Protective Chronic GVHD. Long Term Follow up of 138 Patients.. Blood, 2005, 106, 140-140.	0.6	0
98	Selective Depletion of Alloreacting CD25+ Cells from Stem Cell Allografts Can Reduce Acute Graft-Versus-Host Disease Following Matched Related Donor Transplantation.. Blood, 2004, 104, 426-426.	0.6	2
99	Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anti-Cancer Drugs, 2003, 14, 785-792.	0.7	32
100	Comparative Pharmacokinetics of Unbound Paclitaxel During 1- and 3-Hour Infusions. Journal of Clinical Oncology, 2002, 20, 574-581.	0.8	73